241 related articles for article (PubMed ID: 31572680)
1. Integrated Transcriptome Analysis Reveals KLK5 and L1CAM Predict Response to Anlotinib in NSCLC at 3rd Line.
Lu J; Shi Q; Zhang L; Wu J; Lou Y; Qian J; Zhang B; Wang S; Wang H; Zhao X; Han B
Front Oncol; 2019; 9():886. PubMed ID: 31572680
[TBL] [Abstract][Full Text] [Related]
2. Transcriptome profiling analysis reveals that CXCL2 is involved in anlotinib resistance in human lung cancer cells.
Lu J; Xu W; Qian J; Wang S; Zhang B; Zhang L; Qiao R; Hu M; Zhao Y; Zhao X; Han B
BMC Med Genomics; 2019 Mar; 12(Suppl 2):38. PubMed ID: 30871526
[TBL] [Abstract][Full Text] [Related]
3. Role of anlotinib-induced CCL2 decrease in anti-angiogenesis and response prediction for nonsmall cell lung cancer therapy.
Lu J; Zhong H; Chu T; Zhang X; Li R; Sun J; Zhong R; Yang Y; Alam MS; Lou Y; Xu J; Zhang Y; Wu J; Li X; Zhao X; Li K; Lu L; Han B
Eur Respir J; 2019 Mar; 53(3):. PubMed ID: 30578392
[TBL] [Abstract][Full Text] [Related]
4. Chromatin accessibility analysis reveals that TFAP2A promotes angiogenesis in acquired resistance to anlotinib in lung cancer cells.
Zhang LL; Lu J; Liu RQ; Hu MJ; Zhao YM; Tan S; Wang SY; Zhang B; Nie W; Dong Y; Zhong H; Zhang W; Zhao XD; Han BH
Acta Pharmacol Sin; 2020 Oct; 41(10):1357-1365. PubMed ID: 32415222
[TBL] [Abstract][Full Text] [Related]
5. Screening anlotinib responders via blood-based proteomics in non-small cell lung cancer.
Lu J; Zhang W; Yu K; Zhang L; Lou Y; Gu P; Nie W; Qian J; Xu J; Wang H; Zhong H; Han B
FASEB J; 2022 Aug; 36(8):e22465. PubMed ID: 35867072
[TBL] [Abstract][Full Text] [Related]
6. Role of chemokine-mediated angiogenesis in resistance towards crizotinib and its reversal by anlotinib in EML4-ALK positive NSCLC.
Wang S; Lou N; Luo R; Hao X; Liu Y; Wang L; Shi Y; Han X
J Transl Med; 2022 May; 20(1):248. PubMed ID: 35642002
[TBL] [Abstract][Full Text] [Related]
7. RNA editing enzyme adenosine deaminases acting on RNA 1 deficiency increases the sensitivity of non-small cell lung cancer cells to anlotinib by regulating CX3CR1-fractalkine expression.
Wu M; Jin M; Cao X; Qian K; Zhao L
Drug Dev Res; 2022 Apr; 83(2):328-338. PubMed ID: 34319598
[TBL] [Abstract][Full Text] [Related]
8. The impact of previous therapy strategy on the efficiency of anlotinib hydrochloride as a third-line treatment on patients with advanced non-small cell lung cancer (NSCLC): a subgroup analysis of ALTER0303 trial.
Wang L; He Z; Yang S; Tang H; Wu Y; Li S; Han B; Li K; Zhang L; Shi J; Wang Z; Cheng Y; He J; Shi Y; Chen W; Luo Y; Wu L; Wang X; Nan K; Jin F; Dong J; Li B; Sun Y; Wang Q
Transl Lung Cancer Res; 2019 Oct; 8(5):575-583. PubMed ID: 31737494
[TBL] [Abstract][Full Text] [Related]
9. Anlotinib combined with gefitinib can significantly improve the proliferation of epidermal growth factor receptor-mutant advanced non-small cell lung cancer
Li T; Qian Y; Zhang C; Uchino J; Provencio M; Wang Y; Shi X; Zhang Y; Zhang X
Transl Lung Cancer Res; 2021 Apr; 10(4):1873-1888. PubMed ID: 34012799
[TBL] [Abstract][Full Text] [Related]
10. Levels of pretreatment blood lipids are prognostic factors in advanced NSCLC patients treated with anlotinib.
Tang M; Song C; Zhang Y; Xu X; Wang C; Zhang Z; Chen T
Lipids Health Dis; 2021 Nov; 20(1):165. PubMed ID: 34801029
[TBL] [Abstract][Full Text] [Related]
11. Effect of anlotinib as a third- or further-line therapy in advanced non-small cell lung cancer patients with different histologic types: Subgroup analysis in the ALTER0303 trial.
Cheng Y; Han B; Li K; Wang Q; Zhang L; Shi J; Wang Z; He J; Shi Y; Chen W; Wang X; Luo Y; Nan K; Jin F; Li B; Zhu J
Cancer Med; 2020 Apr; 9(8):2621-2630. PubMed ID: 32064794
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Anlotinib in Patients with Advanced Non-Small Cell Lung Cancer: A Real-World Study.
Zhong Q; Liu Z
Cancer Manag Res; 2021; 13():4115-4128. PubMed ID: 34045898
[TBL] [Abstract][Full Text] [Related]
13. Circulating DNA-Based Sequencing Guided Anlotinib Therapy in Non-Small Cell Lung Cancer.
Lu J; Zhong H; Wu J; Chu T; Zhang L; Li H; Wang Q; Li R; Zhao Y; Gu A; Wang H; Shi C; Xiong L; Zhang X; Zhang W; Lou Y; Yan B; Dong Y; Zhang Y; Li B; Zhang L; Zhao X; Li K; Han B
Adv Sci (Weinh); 2019 Oct; 6(19):1900721. PubMed ID: 31592412
[TBL] [Abstract][Full Text] [Related]
14. Anlotinib Combined with S-1 in the Third-Line Treatment of Stage IV Non-Small Cell Lung Cancer: Study Protocol for Phase II Clinical Trial.
Yang X; Xiang M; Geng L; Wen Y; Du X
Asian Pac J Cancer Prev; 2019 Dec; 20(12):3849-3853. PubMed ID: 31870132
[TBL] [Abstract][Full Text] [Related]
15. Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial.
Han B; Li K; Wang Q; Zhang L; Shi J; Wang Z; Cheng Y; He J; Shi Y; Zhao Y; Yu H; Zhao Y; Chen W; Luo Y; Wu L; Wang X; Pirker R; Nan K; Jin F; Dong J; Li B; Sun Y
JAMA Oncol; 2018 Nov; 4(11):1569-1575. PubMed ID: 30098152
[TBL] [Abstract][Full Text] [Related]
16. A cohort study of the efficacy and safety of immune checkpoint inhibitors plus anlotinib versus immune checkpoint inhibitors alone as the treatment of advanced non-small cell lung cancer in the real world.
Shi Y; Ji M; Jiang Y; Yin R; Wang Z; Li H; Wang S; He K; Ma Y; Wang Z; Lu J; Shi M; Shen B; Zhou G; Leong TL; Wang X; Chen C; Feng J
Transl Lung Cancer Res; 2022 Jun; 11(6):1051-1068. PubMed ID: 35832459
[TBL] [Abstract][Full Text] [Related]
17. Survival benefit of anlotinib in T790M-positive non-small-cell lung cancer patients with acquired osimertinib resistance: A multicenter retrospective study and exploratory in vitro study.
Chen Y; Liu H; Hu N; Wang Y; Yang Z; Zhang J; Han B
Cancer Med; 2023 Aug; 12(15):15922-15932. PubMed ID: 37387596
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of first-line anlotinib-based combinations for advanced non-small cell lung cancer: a three-armed prospective study.
Chu T; Zhang W; Zhang B; Zhong R; Zhang X; Gu A; Shi C; Wang H; Xiong L; Lu J; Qian J; Zhang Y; Dong Y; Teng J; Gao Z; Wang W; Shen Y; Nie W; Lim JU; Mehta HJ; Neal JW; Lou Y; Xu J; Zhong H; Han B
Transl Lung Cancer Res; 2022 Jul; 11(7):1394-1404. PubMed ID: 35958322
[TBL] [Abstract][Full Text] [Related]
19. Low‑dose anlotinib combined with EGFR‑TKI can be used as an alternative for EGFR‑TKI‑resistant non‑small cell lung cancer in elderly patients.
Chen Y; Jiang N; Liang X; Chen N; Chen Y; Zhang C; Shi J; Guo R
Oncol Lett; 2023 Aug; 26(2):323. PubMed ID: 37415629
[TBL] [Abstract][Full Text] [Related]
20. Exosomal miR-136-5p Derived from Anlotinib-Resistant NSCLC Cells Confers Anlotinib Resistance in Non-Small Cell Lung Cancer Through Targeting PPP2R2A.
Gu G; Hu C; Hui K; Zhang H; Chen T; Zhang X; Jiang X
Int J Nanomedicine; 2021; 16():6329-6343. PubMed ID: 34556984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
